The Early Advance Programme is now available. Download it here.

We are busy working on the 2023 programme and will be updating this page regularly.

The key timings for the IPA World Congress + Probiota 2023 to assist with your travel arrangements are:

Monday 6th February:

Tuesday 7th February:

Wednesday 8th February:

13.00 CET Registration

14.00 CET Welcome and sessions begin

18.00 CET Welcome reception

19.00 CET End of day 1

07.15 CET Chr Hansen Run & Walk

09.00 CET Start of day 2

17.30 CET End of day 2 sessions

19.00 CET Probiota Social Evening

21.00 CET End of day 2

09.00 CET Start of day 3

12.50 CET End of day 3 sessions and networking lunch

14.00 CET IPA WC + Probiota 2023 ends

The key themes for the IPA World Congress + Probiota 2023 are:

  • Prebiotics & Synbiotics: Probiotics are the most established category for microbiome enhancement for health, but other categories are growing, including prebiotics, synbiotics and postbiotics. A recent entrant into the prebiotic space are human milk oligosaccharides, which have the potential to improve health throughout our lifespans, not just for infants. This session will explore the science and market potential of these exciting ingredients. Synbiotics are also gain more attention in the marketplace, with consumers exposed to the term from more products. This session will also explore the potential of synbiotics and expand our understanding on their mechanism(s) of action.
  • Continuing the Postbiotics conversation: At our Copenhagen event in 2022, we brought together experts from a range of disciplines to discuss the definition, the science, the business, and consumer understanding of postbiotics. This session will continue the conversation we started in Copenhagen, and outlines the business and health opportunities for this emerging category.
  • The Phage opportunity: The biodiversity of the human gut is significant, including bacteria and fungi, but the gut also contains hundreds of thousands of viruses called bacteriophages, which can modulate the gut microbiota by targeting undesirable bacteria. Recent studies have also revealed correlations between specific phages and health endpoints like cognitive function and memory in humans. Phage-based ingredients are still in their infancy but could become a powerful weapon in the arsenal for microbiome modulation for health and wellness.
  • Personalized microbiome modulation for health and wellness: Everyone’s microbiome is as unique as their own fingerprints, so it seems logical that we could have personalized interventions - prebiotics, probiotics, postbiotics, etc - tailored for the individual. How is the market approaching this currently? What does the science say about personalized probiotics and prebiotics? Are enough consumers willing to pay for this knowledge? How is the athletic community approaching these possibilities? What’s next for this blossoming category? This session will seek to answer these questions and more.
  • The Gut-brain axis: The microbiota-gut-brain axis, that bi-directional interaction between the gastrointestinal tract and the nervous system, has created numerous opportunities to impact mental health, mood, sleep, stress management, cognitive performance and much more. This session will search for answers to a number of questions, including what the science actually says; how well findings from animal studies translate to humans; and which endpoints have the most commercial opportunity.
  • Microbiome modulation for athletic performance: We know that the microbiome of elite athletes is different to non-athletes, but what can we learn to modulate the microbiome to boost performance and recovery in non-athletes? This session will look at the science to date, explore the potential to mine the microbiomes of elite athletes for next-generation probiotics and postbiotics, and consider the wider role for microbiome analysis and modulation in elite sports.
  • Pharmabiotics: With immense interest and investment in approaches to modifying the microbiome to treat disease and health conditions, there are significant opportunities for microbiome-based drug products. But where are the bottle necks in the development? Which health conditions or diseases are attracting the most interest? Where are we on the R&D pipelines? And what lessons can we learn from the investment community about these discoveries?
  • The State of the Market: The pandemic boosted interest in all things microbiome-related, with many companies reporting record sales as consumers sought out products to support their immune systems, help manage stress, and improve their overall health. But what happened during 2022, how has Brexit changed the landscape, and what can we expect in 2023? This session will also explore the regulatory landscape across Europe for probiotics, prebiotics, and postbiotics, and how this may impact the market over the next 12-18 months.
  • View from the aisles: Prebiotics, probiotics & postbiotics at retail This panel brings together leading stakeholders from brands and retail to discuss how e-commerce is disrupting the category, which brands are winning at retail and why, how to communicate microbiome modulators to consumers, and how supply chains impacts are being felt at the retail shelf.

Download the Early Advance Programme to know more.